Zhang Gengtian, Bai Mengyao, Du Hanzhi, Yuan Yue, Wang Yidan, Fan Weijing, Zhu Huachao, Wu Di, He Pengcheng, Xue Busheng
Health Science Center, Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.
Department of Hematology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, People's Republic of China.
Immunotargets Ther. 2025 Jun 27;14:655-680. doi: 10.2147/ITT.S519616. eCollection 2025.
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of refractory hematological malignancies, yet significant challenges persist in extending its success to solid tumors. This review aims to provide a comprehensive overview of the current landscape and future perspectives of CAR-T therapy in both hematological malignancies and solid tumors.
A thorough literature search was conducted to identify relevant preclinical and clinical studies, as well as review articles, focusing on CAR-T therapy in various hematological malignancies and solid tumors. The collected information was synthesized to discuss the current applications, challenges, and strategies for improving CAR-T therapy in these settings.
CAR-T therapy has demonstrated impressive clinical outcomes in treating certain hematological malignancies, such as B-cell lymphoma, leukemia, and multiple myeloma. However, the efficacy of CAR-T cells in solid tumors has been limited due to various obstacles, including tumor heterogeneity, immunosuppressive microenvironment, and off-tumor toxicities. Strategies to overcome these challenges involve advanced CAR designs, combination therapies, and novel approaches to CAR-T cell manufacturing and engineering.
While CAR-T therapy has revolutionized the treatment of some hematological malignancies, significant hurdles remain in extending its success to solid tumors. Continued research efforts focusing on improving CAR-T cell efficacy, safety, and accessibility will be crucial in unlocking the full potential of this innovative immunotherapeutic approach across a broad spectrum of cancer types.
嵌合抗原受体（CAR）T细胞疗法彻底改变了难治性血液系统恶性肿瘤的治疗方式，但要将其成功扩展至实体瘤仍面临重大挑战。本综述旨在全面概述CAR-T疗法在血液系统恶性肿瘤和实体瘤中的现状及未来前景。
进行了全面的文献检索，以识别相关的临床前和临床研究以及综述文章，重点关注CAR-T疗法在各种血液系统恶性肿瘤和实体瘤中的应用。对收集到的信息进行综合分析，以讨论CAR-T疗法在这些情况下的当前应用、挑战以及改进策略。
CAR-T疗法在治疗某些血液系统恶性肿瘤，如B细胞淋巴瘤、白血病和多发性骨髓瘤方面已展现出令人瞩目的临床效果。然而，由于多种障碍，包括肿瘤异质性、免疫抑制微环境和肿瘤外毒性，CAR-T细胞在实体瘤中的疗效受到限制。克服这些挑战的策略包括先进的CAR设计、联合疗法以及CAR-T细胞制造和工程的新方法。
虽然CAR-T疗法彻底改变了一些血液系统恶性肿瘤的治疗方式，但要将其成功扩展至实体瘤仍存在重大障碍。持续专注于提高CAR-T细胞疗效、安全性和可及性的研究工作，对于释放这种创新免疫治疗方法在广泛癌症类型中的全部潜力至关重要。
